Belimumab and Voclosporin: Clinical Insights and Payer Evaluations in Lupus Nephritis

EP: 1.Understanding the Clinical Burden and Prevalence of Lupus Nephritis

EP: 2.Cost Drivers in Lupus Nephritis

EP: 3.Urgency to Treat in Lupus Nephritis: Goals of Therapy and Early Diagnosis Strategies

EP: 4.Guideline Updates in Lupus Nephritis: Impacts on Clinical Decision-Making

EP: 5.Tailoring Lupus Nephritis Treatment: Key Considerations and Specialist Approaches

Now Viewing

EP: 6.Belimumab and Voclosporin: Clinical Insights and Payer Evaluations in Lupus Nephritis

EP: 7.Improving Access to Lupus Nephritis Treatment: Strategies and Resources

EP: 8.Lupus Nephritis Management: Monitoring Strategies and Long-Term Study Results

EP: 9.Collaborating for Better Care: Healthcare Providers and Payers in Lupus Nephritis

EP: 10.From Guidelines to Practice: Advancing Lupus Nephritis Treatment

EP: 11.Looking Ahead: Anticipating Changes in Lupus Guidelines and Clinical Practice

What is your perspective on the differences between the efficacy and safety profiles of belimumab and voclosporin in the treatment of lupus nephritis (LN)? (Dr. Larranaga and Dr. Wells)

How are payers evaluating the value of belimumab and voclosporin in the management of LN? (Dr. Wigginton)

• What does cost-effectiveness look like in LN management?